SGLT2 inhibitors and endothelial function in dilated cardiomyopathy with HFrEF: a 12-month sex-based analysis

9 May 2026 (08:30 - 09:30)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Angelica Cersosimo

Teknon Medical Centre, Barcelona (Spain)

7 More presentations in this session

Presentation thumbnail

Prognostic impact of iron deficiency in patients hospitalised with acute decompensated heart failure with reduced ejection fraction and chronic kidney disease

Doctor V. Dimitrova (Sofia, BG)

Abstract Slides

Presentation thumbnail

Revascularisation strategy in ischemic heart failure: coronary artery bypass grafting versus percutaneous coronary intervention

Doctor A. Ben Salem (Tunis, TN)

Abstract Slides

Presentation thumbnail

Reverse cardiac remodeling and functional improvement with SGLT2 inhibitors in HFrEF: update from REWIN-HFrEF Study

Doctor L. Luzzi (Brescia, IT)

Abstract Slides

Presentation thumbnail

Additional prognostic effect of sacubitril-valsartan and SLGT2-Inhibitors on optimal medical therapy in patients with non-ischaemic dilated cardiomyopathy

Doctor C. Pio Loco detto Gava (Montebelluna, IT)

Abstract Slides

Presentation thumbnail

Association of body mass index with cardiopulmonary efficiency and ventricular remodeling in advanced heart failure

Doctor N. Andjelkovic (Belgrade, RS)

Abstract Slides

Access the full session

Session thumbnail

ePosters in chronic heart failure - heart failure with HFrEF (4)

The Event

Event poster

Heart Failure 2026

9 May 2026 08:30 CET

You may be interested in

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

Webinar

Advanced heart failure therapy in HF patients with preserved and mildly reduced ejection fraction

Congress Session

Transforming heart failure care: unlocking new pathways

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources